

# **PATHOLOGIES DE LA CROISSANCE FŒTALE : ANOMALIES MOLECULAIRES DANS LES SYNDROMES DE BECKWITH WIEDEMANN ET SILVER RUSSELL**

**PR Irène NETCHINE**


Inserm UMR\_S 938, CDR Saint Antoine

Univ. Pierre et Marie Curie Paris 06

AP-HP, Hôpital Trousseau

# CONTRÔLE DE LA CROISSANCE FŒTALE



---





# EMPREINTE PARENTALE : DÉFINITION

---



- > Expression différentielle d'un gène en fonction de son origine parentale



Expression biallélique





Empreinte maternelle




Empreinte paternelle

# L'EMPREINTE : MODÈLE DE RÉGULATION ÉPIGÉNÉTIQUE


> Méthylation de l'ADN




> Modification des histones




> Longs ARN non codants



# RÉGULATION ÉPIGÉNÉTIQUE DE L'EXPRESSION DES GÈNES




# RÉGIONS SOUMISES À EMPREINTE




- Mécanismes :**
- > Duplication/délétion
  - > Mutations
  - > Disomies uniparentales
  - > Perte/gain de méthylation

# LA RÉGION 11P15 CONTIENT DES GÈNES SOUMIS À EMPREINTE




# RÉGULATION DU DOMAINE TÉLOMÉRIQUE



★ : méthylation

# CENTRE D'EMPREINTE ICR1





---



> CTCF : Protection de l'allèle **maternel** contre la méthylation *de novo*  
(mutations des CBS → gain de méthylation sur l'allèle maternel)


# CENTRE D'EMPREINTE ICR1

> Co-localisation CTCF/cohésine à l'origine de conformations allèle-spécifiques de la chromatine



# RÉGULATION DU DOMAINE CENTROMÉRIQUE

---



# SYNDROME DE BECKWITH-WIEDEMANN (BWS)

---

## > Syndrome de croissance excessive


	2013*	1990s
Macroglossie	94%	95%
Macrosomie	43%	88%
Anomalies de paroi abdominale	62%	80%
Organomégalie	44%	60%
Malformations des oreilles	62%	50%
Hypoglycémies néonatales	43%	35%
Angiomes flammeus	45%	30%
Hémi hypertrophie	33%	30%




\* Brioude et al., *Horm Research in Paediatrics* 2013 (in press)

# BWS : MÉCANISMES MOLÉCULAIRES


Mutations de *CDKN1C*



Isodisomies paternelles 11p15




CDKN1C ↘ (activité)  
IGF2 =




↘ CDKN1C  
↗ IGF2

CDKN1C ↘  
IGF2 =

= CDKN1C  
↗ IGF2




Perte de méthylation d'ICR2











Gain de méthylation d'ICR1

# Syndrome de Wiedemann Beckwith: anomalies moléculaires

Mutation du gène *CDKN1C*  
d'origine **maternelle**: 5%



Unidisomie 11p15 **paternelle** : 20-25%



Perte de méthylation **maternelle**  
d'ICR2 : 60%

Gain de méthylation **maternelle**  
d'ICR1 10%

# SYNDROME DE BECKWITH-WIEDEMANN (BWS)

## > Syndrome de croissance excessive


	2013*	1990s
Macroglossie	94%	95%
Macrosomie	43%	88%
Anomalies de paroi abdominale	62%	80%
Organomégalie	44%	60%
Malformations des oreilles	62%	50%
Hypoglycémies néonatales	43%	35%
Angiomes flammeus	45%	30%
Hémihypertrophie	33%	30%
Tumeurs embryonnaires	8.6%	10%



\* Brioude et al., Horm Research in Paediatrics 2013 (in press)


# BWS : MÉCANISMES MOLÉCULAIRES

## Mutations de *CDKN1C*



CDKN1C  $\Downarrow$  (activité)  
IGF2 =


## Isodisomies paternelles 11p15



$\Downarrow$  CDKN1C  
 $\Uparrow$  IGF2


Risque tumoral +++  
(Néphroblastome)

CDKN1C  $\Downarrow$   
IGF2 =



= CDKN1C  
 $\Uparrow$  IGF2

## Perte de méthylation d'ICR2



## Gain de méthylation d'ICR1

# SYNDROME DE SILVER-RUSSELL (SRS)

---

## > **Syndrome de restriction de croissance**

Retard de croissance intra-utérin

Retard de croissance post-natal

Asymétrie corporelle (hémihypotrophie)


Relative macrocéphalie

Grand front bombant

Difficultés alimentaires / IMC < -2 SDS


# SRS : MÉCANISMES MOLÉCULAIRES

## Duplications du domaine centromérique




CDKN1C ↗  
IGF2 =



## Duplications de 11p15



↗ CDKN1C  
= IGF2




= CDKN1C  
↘ IGF2





Perte de méthylation d'ICR1

# Silver Russell Syndrome: 11p15 molecular anomalies subtypes

« Activating » mutation in *CDKN1C* of maternal origin: 1%





Maternal 11p15 duplication: 2-3%



**ICR2**

**ICR1**

Maternal 11p15 ICR2 duplication: 1%



Loss of methylation of the paternal ICR1 : 50-60%

# Allele Specific Methylated Multiplex RTQ-PCR: After Bisulfite Conversion

Hybridization of two allele specific probes stained with two distinct fluorochromes : FAM and VIC.



PCR : non discriminative primers

Elongation → Degradation of the probes




Fluorescence

~ 50% (FAM) ~ 50% (VIC)

♀ ♂





Disruption of the probes after primer extension and release of the fluorochromes





Interrogates 2 to 3 CpG  
Possible with very small DNA quantity  
Very rapid  
Developed for many imprinted regions

# BWS, SRS ET DISOMIES UNIPARENTALES





Isodisomie paternelle de 11p15



Disomie maternelle du chromosome 7


# Interêt des SNP Array

Disomie 11p15 paternelle : 20-25%



CR1=56 [46-56]  
CR2=41 [41-53]

UPD ~10%



Keren, Chantot, Siffroi, communication orale samedi matin

# SOMMAIRE

---

- Anomalies de méthylation des ICR de régions soumises à empreinte sont fréquents dans le SRS et SBW : région 11p15 où se situe *IGF2*, *H19*...
- Suivi de cohortes de patients SBW ou SRS permettra de définir des recommandations de prise en charge thérapeutique et de suivi du risque tumoral
- Il n'y a pas d'anomalie moléculaire identifiée pour environ 40% des patients SRS et SBW.
- Bien que le mécanisme de ces anomalies d'empreinte soit non connu dans la majorité des cas, l'identification d'anomalies génétiques des centres d'empreinte va compliquer le conseil génétique
- Le diagnostic moléculaire de ces anomalies de méthylation en mosaïque est délicat. Le diagnostic prénatal devient techniquement accessible bien que nécessitant une étape encore importante de validation, est-il souhaitable de le développer ?

# SOMMAIRE

---

Si suspicion de SBW ou SRS en foetopathologie:

Nous contacter si possible

Prélèvement non macérés pour étude de la méthylation

avant foeticide, prélèvement de sang en intra cardiaque

après IMG ou FCS :

si possible extraction d'ADN de plusieurs tissus

foie

rein

muscle

poumon



**UPMC**  
SORBONNE UNIVERSITÉS

**Inserm**

Institut national  
de la santé et de la recherche médicale



**Saint-Antoine**

Hôpitaux  
Universitaires  
Paris Est

**TROUSSEAU**  
LA ROCHE-GUYON



ASSISTANCE PUBLIQUE  HÔPITAUX DE PARIS